Shares of Verastem Inc (NASDAQ:VSTM) have been given a consensus rating of “Buy” by the ten analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $10.36.
VSTM has been the topic of a number of research analyst reports. Oppenheimer restated a “buy” rating and set a $15.00 price target on shares of Verastem in a research report on Sunday, December 10th. Cantor Fitzgerald set a $17.00 price target on Verastem and gave the stock a “buy” rating in a research report on Sunday, December 10th. Zacks Investment Research upgraded Verastem from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Cann restated a “buy” rating and set a $13.00 price target on shares of Verastem in a research report on Friday, January 26th. Finally, ValuEngine lowered Verastem from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st.
Verastem (VSTM) opened at $3.16 on Friday. Verastem has a twelve month low of $1.11 and a twelve month high of $5.71. The company has a quick ratio of 3.12, a current ratio of 3.12 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $135.87, a P/E ratio of -1.93 and a beta of 2.20.
Institutional investors and hedge funds have recently made changes to their positions in the business. SeaCrest Wealth Management LLC bought a new position in Verastem in the 4th quarter valued at $108,000. Cubist Systematic Strategies LLC bought a new position in Verastem in the 3rd quarter valued at $136,000. Wells Fargo & Company MN boosted its position in Verastem by 130.5% in the 4th quarter. Wells Fargo & Company MN now owns 45,987 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 26,036 shares during the last quarter. Northern Trust Corp boosted its position in Verastem by 40.3% in the 2nd quarter. Northern Trust Corp now owns 73,750 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 21,178 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in Verastem in the 3rd quarter valued at $195,000. Hedge funds and other institutional investors own 28.72% of the company’s stock.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.